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 Previous studies have shown that the controlled release of adenosine triphosphate 
(ATP) from human erythrocytes is an important mechanism for the regulation of vascular 
caliber.  However, erythrocytes from patients with pulmonary arterial hypertension 
(PAH) fail to release ATP in response to the physiological stimuli of exposure to low 
oxygen tension or mechanical deformation of a magnitude these cells would encounter in 
the pulmonary circulation.  This defect could be a significant contributor to the increased 
pulmonary vascular resistance (PVR) that is the cause of the pathological increase in 
vascular pressures in humans with PAH.   
 One important approach to the treatment of PAH is to reduce PVR with the 
administration of drugs such as prostacyclin or its analogs and phosphodiesterase 5 
(PDE5) inhibitors.  These medications can be used alone or in combination and may have 
serious unwanted side effects that are additive when used in combination. 
 Here an alternative drug delivery technique using drug-loaded liposomes is 
investigated that may allow for increased drug efficacy and, possibly, reduced unwanted 
side effects.  Liposomes can encapsulate drugs and deliver them directly to specific cells.   
This research describes the successful incorporation and delivery of a clinically-used 
PDE5 inhibitor, tadalafil, via liposomes, to human erythrocytes to increase ATP release 
from erythrocytes exposed to the prostacyclin analog, UT-15C.  This demonstrates the 
effectiveness of this technique and forms the basis for future in vivo trials to improve 
drug delivery and patient quality of life.  Liposomal delivery, currently underutilized 
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Symbol           Description 
 AC              adenylyl cyclase 
ADP  adenosine diphosphate 
AMP  adenosine monophosphate 
ATP  adenosine triphosphate 
cAMP  cyclic adenosine monophosphate 
CFTR  cystic fibrosis transmembrane conductance regulator 
cGMP  cyclic guanosine monophosphate 
DM2  diabetes mellitus type 2 
DMPC  1,2-dimyristoyl-sn-glycero-3-phosphocholine 
EDRF  endothelium-derived relaxing factor (nitric oxide, NO) 
FOQELS Fiber Optic Quasi Electric Light Scattering particle size analyzer 
GDP  guanosine diphosphate 
GMP  guanosine monophosphate 
GTP  guanosine triphosphate 




N2  nitrogen  
NO  nitric oxide 
NOS  nitric oxide synthase 
O2  oxygen  
PAH  pulmonary arterial hypertension 
PDE  phosphodiesterase 
PGI2  prostacyclin I2 
PS  1,2-dimyristoyl-sn-glycero-3-phospho-L-serine 
PSS  physiological salt solution 
PVR  pulmonary vascular resistance 




sGC  soluble guanylyl cyclase 
UT-15C United Therapeutics' prostacyclin analog (the oral form of treprostinil) 
VDAC  voltage dependent anion channel 
  
1.  INTRODUCTION 
1.1. PULMONARY CIRCULATION 
 The circulation of blood within the body is necessary for life.  A vital function of 
the circulation is oxygen delivery and waste removal.  However, the system cannot 
operate at maximum capacity at all times.  It is necessary for flow to be directed away 
from over-supplied tissues and delivered to regions of need.  This is achieved in a variety 
of ways.  Although blood flow could be stopped entirely in some areas in order for the 
output of the heart to be directed to other areas, this would be highly detrimental to the 
cells no longer receiving oxygen and nutrients.  Alternatively, flow could be reduced in 
certain areas and increased in others.  One way to achieve this is to increase the diameter 
of blood vessels in the under-supplied region leading to selective increases in blood flow 
to these areas.  However, there must be highly regulated and selective mechanisms that 
control this selective blood vessel dilation. 
 Investigations to explore what controls these vascular changes include those of 
Dr. Persson et al.  This group explored the function of endogenous nitric oxide (NO), also 
known as the endothelium-derived relaxing factor (EDRF) formed in the vascular 
endothelium from L-arginine via the activity of the enzyme nitric oxide synthase (NOS).  
NO induces vascular smooth muscle relaxation resulting in increases in vascular diameter 
(decreases in vascular resistance) in the pulmonary circulation [1].   
 Pulmonary vascular resistance (PVR) increases substantially in response to 
decreases in the oxygen tension in the alveoli of the lungs (hypoxic pulmonary 
vasoconstriction).  This vasoconstriction is potentiated by the application of N
G
-nitro-L-
arginine methylester (L-NAME), an inhibitor of NOS [2,3].  These findings suggest that 
NO plays a critical role in the determination of vascular resistance in the lung.  However, 
these studies did not reveal what stimulated the production of NO in the pulmonary 
circulation under these conditions.  The data in support of the role of erythrocyte-derived 
adenosine triphosphate (ATP) as a stimulus for NO synthesis in the pulmonary 
circulation is described in the next sections. 
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1.1.1. A Critical Effector of Vascular Dilation in the Pulmonary Circulation.  
Experiments using isolated, blood-perfused rabbit lungs treated with N
G
-nitro-L arginine 
methyl ester (L-NAME), an inhibitor of NO synthesis, or its vehicle showed a significant 
increase in pressure in response to increases in flow rate when NO synthesis was 
prevented [3].  This demonstrates that NO is important in the regulation of vascular 
resistance.   
In separate studies, it was shown that inhibition of NO synthesis resulted in a 
reduction in blood flow to portions of the lung that were hypoxic.  One interpretation of 
this result is that NO was synthesized in areas of increased pulmonary vascular resistance 
and was opposing vasoconstriction [2]. 
1.1.2. Role of Blood Components in the Synthesis of NO in the Pulmonary 
Circulation.  Blood consists of red blood cells (erythrocytes, RBCs), white blood cells 
(leukocytes), platelets, and plasma.  Each component serves a specific function.  The 
research presented in this dissertation focuses on the element that affects vasodilation.  
The contribution of blood components to pulmonary vascular resistance was investigated 
in studies in isolated rabbit lungs, perfused with whole blood, plasma, erythrocytes, or a 
dextran-containing physiological salt solution (PSS).  When lungs were perfused with 
blood or isolated RBCs suspended in PSS (at a hematocrit of 20% or greater) inhibition 
of NO synthesis with L-NAME resulted in significant increases in pulmonary vascular 
resistance when flow rates were increased [4].  In contrast, when the lungs were perfused 
with either plasma containing normal numbers of platelets and white blood cells but 
without erythrocytes or PSS containing dextran to increase viscosity to that of whole 
blood, L-NAME had no effect on flow-induced increases in vascular pressure.  These 
studies demonstrated that RBCs were required for flow-induced increases in NO 
synthesis in the pulmonary circulation. 
1.1.3. Mechanism of Erythrocyte-induced Increases in NO Synthesis in the 
Pulmonary Circulation.  To investigate what property of the RBC is necessary to 
stimulate the synthesis of NO under the conditions described above, experiments were 
performed by Sprague et al. using human or dog RBCs perfused through isolated rabbit 
lungs.  L-NAME increased pulmonary vascular resistance only in lungs perfused with 
human RBCs [5]. 
  
3 
In order to determine why dog RBCs failed to stimulate NO synthesis under these 
conditions, RBCs from both species were subjected to mechanical deformation as would 
be encountered as these cells traverse the pulmonary circulation using a St. George’s 
Blood Filtrometer.  This device contains a filter with pores of 12, 8, or 5 µm.  Human 
erythrocytes are approximately 7-8 µm [6].  Passage through smaller pores force the 
RBCs to flex to pass through when pulled by hydrodynamic forces. The amount of ATP 
that was released as the cells were deformed was then measured in the filter effluent.  
ATP was only found in the effluent when human RBCs were passed through the filters.  
These findings are consistent with the hypothesis that the ability of RBCs to release ATP 
when they pass through the pulmonary circulation plays an important role determining 
vascular diameter in that vascular bed.   
Importantly, in addition to deformation, ATP is released from human erythrocytes 
via additional mechanisms including activation of the prostacyclin receptor (IPR) that is 
present in these cells [7].  The signaling pathways involved in ATP release in response to 
these stimuli have been characterized and have important differences.  For example, in 
these pathways, the initial step is the activation of a different heterotrimeric G protein and 
the final conduit for ATP release differs [8-11].   
 
1.2. PULMONARY CIRCULATION CONTROL 
The pathway shown in Figure 1.1 illustrates the proposed method of signal 
transduction within the erythrocyte to initiate ATP release in response to prostacyclin 
stimulation [7].  Prostacyclin (PGI2) or its analogs (such as UT-15C) bind to the 
prostacyclin receptor (IPR) [7] which activates the alpha subunit of the heterotrimeric G-
protein Gs [9] via hydrolysis of guanosine triphosphate (GTP) into guanosine diphosphate 
(GDP) [12]. This active form of the alpha subunit then activates adenylyl cyclase (AC) 
[13] to hydrolyze ATP into cyclic adenosine monophosphate (cAMP) [14].  In this 
pathway, cAMP then activates the cAMP-dependent protein kinase (PKA) [15] which in 
turn activates the cystic fibrosis transmembrane conductance regulator (CFTR) [16].  
ATP release is through the voltage dependent anion channel (VDAC) [10].  In the 
pulmonary vasculature, the released ATP binds to the purinurgic receptor 2y (P2Y) that 





Figure 1.1. Erythrocyte:  Proposed Prostacyclin Signal Transduction Pathway. 
Abbreviations:  IPR = PGI2 receptor; Gs = heterotrimeric G protein, Gs; AC = adenylyl 
cyclase; ATP = adenosine triphosphate; cAMP = cyclic adenosine monophosphate; AMP 
= adenosine monophosphate; PKA = protein kinase A; CFTR = cystic fibrosis 
transmembrane conductance regulator; VDAC = voltage-dependent anion channel; GTP 
= guanosine triphosphate; cGMP = cyclic guanosine monophosphate; GMP = guanosine 
monophosphate;  sGC = soluble guanylyl cyclase; PDE3 = phosphodiesterase 3; PDE5 = 
phosphodiesterase 5; (+) = activation and (−) = inhibition 
 
 
 In all cellular signaling pathways, there are components that act to regulate the 
magnitude and duration of activity.  In the IPR pathway in erythrocytes, increases in 
cAMP are critical for ATP to be released, making the control of the levels of this cyclic 
nucleotide an ideal point for regulation of the pathway [7,18].  The level of cAMP 
present in the erythrocyte when this pathway is activated is a product of its synthesis by 
AC and its hydrolysis by phosphodiesterase 3 (PDE3) [19].  PDE3 can, in turn, be 
inhibited by increases in cyclic guanosine monophosphate (cGMP).  Erythrocyte levels of 
cGMP are regulated by phosphodiesterase 5 (PDE5) [20].  Thus, amounts of ATP 
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released from erythrocytes following activation of the IPR are regulated by the activity of 
both PDE3 and PDE5. 
The pathway for deformation-induced ATP release is similar to the IPR pathway 
but differs in two important ways (Figure 1.2) [13,21,22].  In contrast to the IPR pathway, 
this pathway requires activation of the heterotrimeric G-protein Gi instead of Gs and the 
final conduit is pannexin 1 [22-24].  These two pathways allow the RBC to respond to 





Figure 1.2.  Erythrocyte:  Proposed Deformation Signal Transduction Pathway. 
Abbreviations:  IPR = PGI2 receptor; Gi = heterotrimeric G protein, Gi; AC = adenylyl 
cyclase; ATP = adenosine triphosphate; cAMP = cyclic adenosine monophosphate; AMP 
= adenosine monophosphate; PKA = protein kinase A; CFTR = cystic fibrosis 
transmembrane conductance regulator; VDAC = voltage-dependent anion channel; GTP 
= guanosine triphosphate; cGMP = cyclic guanosine monophosphate; GMP = guanosine 
monophosphate;  sGC = soluble guanylyl cyclase; PDE3 = phosphodiesterase 3; PDE5 = 
phosphodiesterase 5; (+) = activation and (−) = inhibition. 
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 1.2.1. Prostacyclin. To increase ATP release from RBCs, prostacyclin or one of 
its analogs can be administered clinically.  ATP release occurs via the pathway presented 
in Figure 1.1.  A minimal amount of UT-15C is necessary to stimulate ATP release [7].  
Unfortunately, in PAH patients, prostacyclin and its analogs have been reported to have 
significant side effects that can increase with increased dosage [25].  Partly in an effort to 
reduce some of these side effects, phosphodiesterase (PDE) 5 inhibitors can be prescribed 
to reduce the amount of UT-15C that is administered but maintain the desired decrease in 
PVR [26-28].  Importantly, this combination can stimulate increased ATP release from 
human RBCs [26,29]. However, a minimal amount of prostacylin or prostacyclin analog 
is necessary even in the presence of a PDE5 inhibitor.   
 1.2.2. Deformation-induced ATP Release. Similar to prostacyclin stimulation, 
deformation also stimulates human erythrocytes to release ATP [16,30].  The associated 
signaling pathway is illustrated in Figure 1.2.   
  
1.3. LIPOSOMES 
 Unfortunately, PDE inhibitors have significant unwanted side effects [31-33].  For 
this reason, it is advantageous to minimize undesired interactions.  Directed delivery of 
drugs to specific cells could reduce side effects.  One such method is the liposome, a 
small lipid vesicle that encapsulates a drug and targets delivery to specific cells [34-36].  
For PAH patients, it would be beneficial to deliver drugs, in particular, PDE5 inhibitors, 
directly to RBCs.  This method has been shown to increase drug efficacy and tolerability 
[37-41].  In fact, liposomal delivery of the PDE3 inhibitor, cilostazol, has recently been 











2. POTENTIAL ROLE OF LIPOSOMES FOR THE DELIVERY OF 
PHOSPHODIESTERASE INHIBITORS TO ERYTHROCYTES FOR THE 
TREATMENT OF TYPE 2 DIABETES 
 It is estimated that there are more than 300 million individuals with type 2 
diabetes (DM2) world-wide making this disease a major public health challenge [43].  
Impaired vascular function is a significant complication of DM2 with cardiovascular 
disease accounting for nearly half of the deaths in humans with this condition [44,45].  
Individuals with DM2 have a four-fold increased risk for claudication [46] and as much 
as a sixteen-fold increased risk for lower limb amputation [47-49].  Although this 
vascular disease is, in part, the result of an increased incidence of atherosclerosis in large 
conduit vessels [16], there is also extensive evidence that microvascular circulatory 
control is abnormal in humans with DM2 [50-53].   
 Patients with DM2 have diminished muscle blood flow both at rest [51] and with 
exercise [53].  Although direct studies of the skeletal muscle microcirculation are not 
possible in humans, such studies have been undertaken in several animal models of 
diabetes [54-56].  These studies demonstrate marked reductions in: 1) oxygen delivery 
[54,56], 2) capillary erythrocyte flux [55] and 3) convective oxygen delivery and 
diffusive oxygen transport [54].  Taken together, these reports indicate that, in DM2, 
oxygen delivery to skeletal muscle in amounts required to appropriately meet metabolic 
need is impaired.   
 It has been suggested that both endothelium-dependent and endothelium-
independent vasodilation is impaired in humans with DM2 [57-61].  It has also been 
suggested that there is reduced nitric oxide (NO) synthesis [58], increased NO 
degradation [59] and/or abnormalities in the vascular smooth muscle [60] in these 
individuals.  These reports demonstrate that, although vasodilation in response to both 
pharmacological and physiological stimuli is impaired in humans with DM2, the 








2.1. ROLE OF ERYTHROCYTES IN THE CONTROL OF THE DISTRIBUTION  
       OF PERFUSION IN THE MICROCIRCULATION 
Although the erythrocyte is often considered to be primarily a cell dedicated to 
the transport and delivery of oxygen to the tissues, this cell has also been shown to 
participate in the regulation of vascular caliber [22,57,62-66].  In skeletal muscle, a 
critical stimulus for local dilation of blood vessels is the release of the vasodilator, ATP 
from erythrocytes exposed to low oxygen tension [22,57,62-66].  Indeed, this property of 
erythrocytes to stimulate vasodilation specifically in areas of decreased oxygen tension 
(increased oxygen utilization relative to supply) can influence the distribution of blood 
flow in the microcirculation of skeletal muscle resulting in optimal matching of the 
delivery of oxygen with need [65-67].  In humans with type 2 diabetes (DM2), the ability 
of erythrocytes to release ATP in response to exposure to low oxygen tension is severely 
impaired [68-70].   
 
2.2. A SIGNALING PATHWAY FOR LOW OXYGEN-INDUCED ATP RELEASE  
       FROM ERYTHROCYTES  
ATP is a highly charged molecule that does not freely cross cell membranes.  
Therefore, the regulated release of ATP from erythrocytes requires the presence of 
signaling pathways that respond to discrete stimuli (Figure 1.2).   Low oxygen tension-
induced ATP release requires activation of the heterotrimeric G-protein Gi [22].  In this 
signaling pathway, the next steps require sequential activation of adenylyl cyclase (AC) 
[13,18], protein kinase A (PKA) [15] and the cystic fibrosis transmembrane conductance 
regulator (CFTR) [16,71].  The final ATP conduit in this signaling pathway is pannexin 
1[11].  Importantly, it has been shown that expression of a single Gi isoform (Gi2) is 
reduced in erythrocytes of humans with DM2 [69,70] and is associated with markedly 
reduced ATP release in response to exposure of these cells to low oxygen tension [68,70].  
Although no mechanism to increase Gi2 expression in DM2 erythrocytes has been 
proposed, it has been reported that pharmacological approaches can increase the activity 
of the low oxygen signaling pathway for ATP release from these cells.  
 Cyclic AMP is a critical second messenger in pathways for ATP release from 
erythrocytes [13,15].  In all cells, cAMP levels must be tightly regulated for activation of 
signaling pathways and associated cellular responses discrete.  In the low oxygen 
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pathway for ATP release from erythrocytes, levels of cAMP are regulated by PDE3 
[14,20] (Figure 1.2).  Importantly, inhibitors of PDE3 activity have been shown to 
potentiate cAMP levels and increase ATP release in response to low oxygen tension in 
erythrocytes of humans with DM2 [72].  However, in clinical use, systemic 
administration of PDE3 inhibitors has been reported to have adverse cardiovascular 
effects that limit the use of such drugs in humans with DM2 [73].  If PDE3 inhibitors 
could be delivered selectively to erythrocytes, it is possible that such adverse effects 
could be minimized.  One approach for the selective delivery of drugs to erythrocytes is 
via the use of liposomes [74,75].  
 
2.3. LIPOSOME CONSTRUCTION 
 Liposomes may be composed of one or many bilayer membranes (unilamellar or 
multilamellar).  They can range in size from a few nanometers to several micrometers in 
diameter.  Measurement of liposomal size can be determined by several methods 
including light scatter [76], flow cytometry [77], and electron microscopy [78].  In 
addition to size, the number of membranes in a liposome can affect its ability to release 
its contents into a cell once it fuses with the membrane of the target cell [79]. 
 When constructing liposomes, different phospholipids can be selected on the basis 
of their charge to result in desired surface properties of the liposomal membrane.  The 
electrical charge of a liposome can affect its binding affinity for different cell types [79-
81].  Specifically, negative charges appear to be beneficial for the fusion of liposomes 
with erythrocytes [79,80].  Although positive charges have also been used, the incidence 
of hemolysis of erythrocytes was increased under these conditions [78,81].   
 In addition to total charge, different lipids used to construct liposomes contain 
different numbers and/or arrangements of atoms as well as single or double bonds which 
allow these molecules to be even more individualized [80]. Cholesterol and other 
components are often added to liposomes to stabilize their membranes, to more closely 
model cellular membranes, and/or to alter binding or fusion of liposomes to cells [82,83].  
These alterations can affect the fluidity of the liposomal membrane.  Membrane fluidity 
strongly affects the likelihood of fusion between liposomes and cells [34].  Importantly, 
liposomes with increased membrane fluidity were reported to display enhanced binding 
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with erythrocytes [84].  Other components that may be added to liposomes to enhance 
selective binding of liposomes to specific cell types or tissues include selective antibodies 
[39,85,86] or other molecules to decrease recognition of liposomes by the immune 
system [76].  In addition to the molecular constituents of liposomes, the medium in which 
liposomes and cells are incubated as well as the length of time, concentration, and 
temperature can also strongly influence the effectiveness of subsequent liposome-cell 
interactions and fusion events [37,82].  Thus, liposome-erythrocyte interactions are 


























3. LIPOSOMAL-DELIVERY OF PHOSPHODIESTERASE 5 INHIBITORS 
AUGMENTS UT-15C-INDUCED ATP RELEASE FROM HUMAN 
ERYTHROCYTES 
Erythrocytes have been shown to participate in the regulation of vascular caliber 
via the release of the potent vasodilator, ATP [61,22,65,88].  ATP is released from 
erythrocytes in response to both physiological and pharmacological stimuli [5,7].  
Erythrocytes of humans with pulmonary arterial hypertension (PAH) fail to release ATP 
when exposed to one physiological stimulus, namely, mechanical deformation as would 
be encountered when these cells traverse the microcvasculature [13].  In contrast, PAH 
erythrocytes do release ATP when exposed to prostacyclin (PGI2) analogs via a well-
characterized signaling pathway that requires increases in intracellular cAMP (Figure 
1.1) [7,26,29]. In this pathway, levels of cAMP are regulated by PDE3, a PDE that is 
inhibited by local increases in cyclic guanosine monophosphate (cGMP) [14].  
Erythrocytes make cGMP; its levels are the product of synthesis by soluble guanylyl 
cyclase (sGC) and hydrolysis by PDE5 [20].  Importantly, inhibitors of PDE5 have been 
shown to augment PGI2 analog-induced ATP release from both healthy human and PAH 
erythrocytes [26,29].  Although both PGI2 analogs and PDE5 inhibitors are used in the 
treatment of PAH, the effectiveness of these drugs alone or in combination is sometimes 
limited by untoward systemic side effects including hypotension, flushing and headache 
[25,33].   If PDE5 inhibitors could be targeted to erythrocytes, it is possible that some of 
these side effects could be minimized while augmentation of PGI2 analog-induced release 
of ATP from these cells would be preserved. 
 Liposomes can target drug delivery to specific cells, including erythrocytes 
[35,40].  However, the construction of liposomes that are both compatible with human 
erythrocytes and capable of carrying and delivering a PDE5 inhibitor has not been 
previously reported.  Here it is reported that liposomes loaded with PDE5 inhibitors 
augment ATP release from human erythrocytes exposed to UT-15C, an oral form of the 
prostacyclin analog, treprostinil. These findings demonstrate that encapsulation of PDE5 
inhibitors within liposomes is a viable approach to the delivery of these drugs to human 
erythrocytes.  Delivery of PDE5 inhibitors to erythrocytes via liposomes could benefit 
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PAH patients by reducing the off-target drug effects while maintaining the therapeutic 
effect of a reduction in pulmonary vascular resistance.  
 
3.1. MATERIALS AND METHODS 
 The materials and methods used for these experiments are defined in the 
following subsections.  All experiments were conducted at the Missouri University of 
Science and Technology. 
3.1.1. Isolation of Human Erythrocytes. Blood obtained from healthy human 
volunteers was collected into heparinized tubes at the Phelps County Regional Medical 
Center or Saint Louis University and transported to the Missouri University of Science 
and Technology where it was centrifuged at 500g at 4°C for 10 min.  The plasma, buffy 
coat, and uppermost layer of erythrocytes were removed by aspiration [5,7,13,26].  Care 
was taken to remove the fewest erythrocytes possible.  The remaining erythrocytes were 
resuspended and washed in a physiological salt solution (PSS) containing (in mM): 21.0 
tris (hydroxymethyl) aminomethane, 4.7 KCl, 2.0 CaCl2, 140.5 NaCl, and 1.2 MgSO4.  
For erythrocyte washing and purification, 5.5 mM glucose and 0.5% bovine serum 
albumin fraction V were added and the pH adjusted to 7.4.   Erythrocytes were prepared 
on the day of use.  Informed consent was obtained from all volunteers.  The protocol for 
blood removal was approved by the Institutional Review Boards of the Phelps County 
Regional Medical Center, the Missouri University of Science and Technology, and Saint 
Louis University.  All record keeping was in compliance with regulations of the Health 
Insurance Portability and Accountability Act. 
3.1.2. Generation of DMPC Liposomes. Unilamellar liposomes were prepared 
by the extrusion method [89].  DMPC (10mg) was added to a mixture of 
methanol/chloroform (50/50, v/v) in the absence (blank, control) or presence of the PDE3 
inhibitor, cilostazol (CILO, 2mM; Sigma-Aldrich, St. Louis, MO, USA), or either of two 
PDE5 inhibitors, zaprinast (ZAP, 1mM; Sigma-Aldrich) or tadalafil (TAD, 1mM; Eli 
Lily, Indianapolis, IN, USA).  A stream of purified argon was used to evaporate the 
solvents to form a lipid/drug film on the walls of a microcentrifuge tube spun at 300 rpm 
in a Heidolph RZR stirrer (Heidolph Instruments, Cinnaminson, NJ, USA).  The film was 
further dried under vacuum to remove traces of chloroform and methanol.  The dried film 
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was rehydrated with 0.5 mL of PSS (without glucose or albumin) creating a dispersion of 
multilamellar vesicles.  The solution was then extruded through two polycarbonate 
membranes with 100 nm pores eleven times using an Avanti Mini-extruder (Avanti Polar 
Lipids, Alabaster, Alabama, USA).  
3.1.2.1. Generation of fluorophore-containing liposomes. The 
fluorophore-containing molecule, 25-NBD cholesterol (Avanti Polar Lipids) in 
chloroform, was added as the chloroform volume to the 50/50 v/v methanol/chloroform 
DMPC mixture prior to evaporation, rehydration with PSS, and extrusion.  The sample 
was protected from exposure to light [90,91].  
3.1.2.2. Generation of cholesterol-containing liposomes. Cholesterol (4.3mg, 
Avanti Polar Lipids) was added to 10mg DMPC and mixed in 60/40 v/v 
methanol/chloroform in the absence (blank, control) and presence of TAD prior to 
evaporation under a stream of argon during low speed centrifugation.  After further 
drying under vacuum, 0.5 mL PSS was used to rehydrate the lipid film prior to extrusion 
[42,92].   
3.1.2.3. Generation of phospho-L-serine-containing liposomes. 1,2-
dimyristoyl-sn-glycero-3-phospho-L-serine (14:0, PS; Avanti Polar Lipids), 30% w/w, 
was added to 70% w/w DMPC in 50/50 v/v methanol/chloroform prior to evaporation 
and rehydration with 0.5mL PSS before extrusion [87,93]. 
3.1.3. Measurement of ATP.  Washed erythrocytes were diluted with PSS 
containing glucose and albumin to a hematocrit of 20%.  The luciferin-luciferase 
technique [5,94] was used to measure ATP.  Briefly, a 0.2 mL sample of an erythrocyte 
suspension (0.04% hematocrit) was injected into a cuvette containing 0.1 mL of 10 
mg/mL crude firefly lantern extract (Sigma) and 0.1 mL of 0.5 mg/mL D-luciferin 
(Research Products International, Mt. Prospect, IL, USA).  The emitted light was 
detected with a luminometer (Turner Biosystems, Sunnyvale, CA, USA).  An ATP 
standard curve was generated on the day of each study.  ATP levels were measured at 
baseline and 5, 10 and 15 min after administration of UT-15C (United Therapeutics, 
Silver Spring, MD, USA). The peak value obtained is reported as nanomoles normalized 
to 4 x 10
8
 erythrocytes.  Cells were counted using a hemocytometer.   
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3.1.4. Measurement of Free Hemoglobin. Erythrocyte suspensions were 
centrifuged at 500g for 10 min at 4°C.  The presence of free hemoglobin in the 
supernatant was measured using light absorption at 405 nm [16,95].  This method was 
used to detect and eliminate studies in which free hemoglobin levels increased indicating 
the presence of significant hemolysis.  No studies were excluded due to increased 
hemoglobin levels. 
3.1.5. Determination of the Effect of Various Concentrations of UT-15C on 
ATP Release from Human Erythrocytes in the Absence or Presence of the PDE5 
Inhibitor, ZAP. Erythrocytes were diluted to a hematocrit of 20% in PSS containing 
glucose and albumin.  Samples were pretreated with ZAP (10µmol/L) or its vehicle, 
dimethyl formamide (DMF), for 30 minutes prior to the measurement of ATP (baseline) 
and 5, 10, and 15 min after addition of UT-15C at concentrations of 10, 30 or 100 
nmol/L.  The peak ATP release is reported. 
3.1.6. Measurement of Liposomal Binding to Erythrocytes Using Flow 
Cytometry. Erythrocytes were isolated and diluted to 20% with PSS containing glucose 
and albumin.  Aliquots of the mixture were then incubated with 10 µL/mL liposomes, 
which did or did not contain the fluorophore (25-NBD cholesterol), for 10 min at room 
temperature in the dark.  Samples were read on a BD Accuri C6 Flow Cytometer 
(Becton, Dickenson, and Co., Franklin Lanes, NJ, USA) equipped with a solid state 
50mW laser tuned to 488nm. A 200µm ID fused silica capillary flow cell was used at a 
flow rate of 10µL/min with no gating and a threshold of 10,000 events.  Forward and side 
scatter conditions remained unchanged through all tests.  The measurable particle size 
range for this device is 1-40µm [77,96]. 
3.1.7. Investigation of Rheological Changes in Erythrocytes in the Absence or 
Presence of Liposomes. To determine if liposome-erythrocyte interactions resulted in 
any alterations in erythrocyte deformability, rheological studies were performed with the 
Anton Paar Modular Compact Rheometer 302 (Anton Paar, Ashland, VA, USA) at 20°C 
using parallel plate configuration (50mm diameter, 0.05mm gap) [97].  Isolated 
erythrocytes were diluted to a 40% hematocrit with PSS containing glucose and albumin 
then incubated with liposomes or saline prior to testing.  Comparison of the apparent 
viscosity relative to shear rate via resistance measurements were made with increasing 
  
15 
oscillations over time.  The presence of differences between treatment groups would 
demonstrate significant rheological alterations caused by the liposomes.   
3.1.8. Determination of the Effect of UT-15C on ATP Release from Human 
Erythrocytes in the Presence of Blank Liposomes or Liposomes Containing Various 
PDE Inhibitors. Erythrocytes were diluted to a hematocrit of 20% in PSS containing 
glucose and albumin.  Samples were pretreated with either blank liposomes or liposomes 
containing either the PDE3 inhibitor, CILO, or one of two PDE5 inhibitors, ZAP or TAD, 
for 30 min.  ATP levels were then determined before and at 5, 10, and 15 min after the 
addition of UT-15C (1µmol/L).  The peak ATP release is reported. 
3.1.9. Data Analysis. Statistical differences among groups were determined using 
an analysis of variance followed by a Fisher’s least significant difference (LSD) test.  
When possible, results are reported as mean ± the standard error (SE).   
 
3.2. RESULTS  
 The following results were obtained using the methods above.  The data is 
presented in the form of graphs or tables to best present the concept supported.   
 3.2.1. Effect of UT-15C on ATP Release from Erythrocytes in the Absence or 
Presence of ZAP. Erythrocytes were incubated with the PGI2 analog, UT-15C, at 
concentrations of either 10 (n=3), 30 (n=7), or 100 (n=7) nmol/L. In the absence of ZAP, 
these concentrations of UT-15C did not stimulate ATP release (Figure 3.1).  In contrast, 
in the presence of ZAP (10µmol/L), ATP release was stimulated by UT-15C at 
concentrations of 30 and 100 nmol/L (Figure 3.1).   
3.2.2. Use of Flow Cytometry to Characterize Liposome-binding to 
Erythrocytes. Using flow cytometry, solutions of erythrocytes, liposomes, or both 
passed a laser emitting light of a specific wavelength (488nm).  Detectors along the flow 
path recorded ―events‖ (wavelengths of light) which were distinguished when excited 
molecular fluorophores emitted light at 523nm.  Analysis of the locations of the detectors 
recording events estimated cell size.  Larger cells exhibited greater forward scatter (FSC) 
whereas granular cells exhibited greater side scatter (SSC).  Figure 3.2 provides paired 





Figure 3.1. ATP Release without Liposomes.  Effect of UT-15C (10, 30 or 100 nmol/L, n 
= 3, 7, and 7, respectively) on ATP Release from Human Erythrocytes in the Presence of 
Zaprinast (ZAP, 10 µmol/L) or Its Vehicle (dimethyl formamide, DMF).  
 
 
Erythrocytes alone (Figures 3.2A and 3.2D) are relatively large (7-8µm, as shown 
in Figure 3.2A) and do not fluoresce, shown by the majority (95.6%) of events at 
channels below the marked threshold (Figure 3.2D).  Liposomes made with DMPC alone 
(Figures 3.2B and 3.2E) are small or granular (~100nm, Figure 3.2B) and do fluoresce as 
shown by the greatest volume of events (76.9%) occurring at channels above the marked 
threshold (greater wavelength, Figure 3.2E).  When erythrocytes were incubated with 
liposomes containing a fluorophore, the large cells (erythrocytes) exhibited fluorescence 
from binding with labeled liposomes (Figures 3.2C and 3.2F).  Examination of the 
supernatant of erythrocytes that had been incubated with fluorophore-containing 
liposomes did not display fluorescence indicating that the vast majority of liposomes 







Figure 3.2. Flow Cytometry Graphs.  Scatter Plots (A-C) and Histograms (D-F) of 







3.2.3. Determination of Rheological Effects of DMPC Liposomes on 
Erythrocytes. Comparison of the apparent viscosity of erythrocyte suspensions at  
different applied shear rates revealed no differences between samples incubated with or 
without liposomes (Figure 3.3).  As the concentration of erythrocytes and the suspending 
medium were kept constant, no measurable change in erythrocyte morphology or 
deformability was detected.   
3.2.4. Effect of UT-15C on ATP Release from Erythrocytes in the Absence 
and Presence of DMPC-containing Liposomes without and with CILO or ZAP. 
Erythrocytes incubated with liposomes containing CILO failed to release ATP in 
response to UT-15C administration.  In contrast, when erythrocytes were incubated with 
liposomes containing the PDE5 inhibitor, ZAP, the same concentration of UT-15C 
stimulated the release of ATP (Figure 3.4).  These results demonstrate that although 
DMPC liposomes delivered the PDE5 inhibitor to human erythrocytes, this composition 




Figure 3.3. Rheometry. Rheometric Comparison of the Apparent Viscosity at Increasing 




























3.2.5. Effect of UT-15C on ATP Release from Erythrocytes in the Absence 
and Presence of Cholesterol- or PS-containing Liposomes without and with the 
PDE5 Inhibitor, TAD. Figure 3.5 displays the influence on ATP release by different 
lipids.  Incubation of erythrocytes with cholesterol-containing liposomes resulted in a 
significant increase in baseline ATP levels compared to those in other liposome 
preparations (Figure 3.5A).  However, with these cholesterol-containing liposomes, an 
increase in ATP release following stimulation with UT-15C was seen in both the absence 
and presence of the PDE5 inhibitor, TAD (Figure 3.5A).  Hemoglobin levels in the 
supernatant of erythrocytes treated with cholesterol-containing liposomes were not 
increased suggesting that the increased ATP levels were not the result of hemolysis.   
Figure 3.4. ATP Release Using Different PDE Inhibitors. Effect of UT-15C (1 µmol/L) 
on ATP Release from Human Erythrocytes in the Presence of Blank DMPC Liposomes 
(CONTROL) or Liposomes of the Same Composition Loaded with Either the PDE3 




Figure 3.5. ATP Release Using Different Lipids. Effect of UT-15C (1 mol/L) on ATP 
Release from Human Erythrocytes in the Presence of Blank DMPC Liposomes 
(CONTROL) Containing Cholesterol (Panel A) or Phospho-serine (PS, Panel B) or 





In contrast to the results with cholesterol-containing liposomes, erythrocytes 
exposed to liposomes containing PS had lower baseline values (Figure 3.5B) but failed to  
release ATP when exposed to UT-15C.  Taken together, these studies demonstrate that 
liposome composition is of critical importance in delivering TAD to human erythrocytes. 
3.2.6. Effect of UT-15C on ATP Release from Erythrocytes in the Absence 
and Presence of DMPC-containing Liposomes without and with TAD. ATP release 
was stimulated by UT-15C when DMPC liposomes were used to deliver TAD to 
erythrocytes (Figure 3.6).  These findings demonstrate that when generating liposomal 
membranes for effective delivery of PDE5 inhibitors to human erythrocytes the 
phospholipid used must be carefully selected and that sterols are detrimental in this 
application.  
Figure 3.6. ATP Release Using DMPC. Effect of UT-15C (1 µmol/L) on ATP Release 
from Human Erythrocytes in the Presence of Blank DMPC Liposomes (CONTROL) or 




4.  SUPPORTING EXPERIMENTATION 
 The previous two chapters contain information that has been submitted to 
scientific journals.  This chapter presents information that was presented in poster format 
or has been used to help support experimental conclusions.  Due to novelty (either in the 
experimental procedure or in methodological experience) or a lack of completeness, this 
data has not been submitted for inclusion in a scientific journal. 
 
4.1. DETERMINATION OF LIPOSOME SIZE 
 It is important when utilizing liposomes to be cognizant of their size.  Not only 
does size affect the volume of material that can be contained within the liposome [98.99] 
but it is also important to consider how these vesicles will compare and interact in the 
body and with the desired cells [41,42].  Two methods were employed to investigate 
liposomal size.  Other methods also exist [77,78,100]. 
 4.1.1. Density Light Scatter. One method to determine liposomal diameter is by 
dynamic light scatter (DLS) [77].  Although somewhat time consuming, this commonly 
accepted technique involves the measurement of the Doppler broadening of Rayleigh 
scattered light due to thermal (Brownian) motion [101].  Smaller particles move within 
the solution more rapidly than do large particles and therefore scatter light more 
frequently.   
Using a Brookhaven Fiber Optic Quasi Electric Light Scattering (FOQELS) 
particle size analyzer at an angle of 135.8°, the data in Table 4.1 shows was generated.  
The dispersity index, previous called the polydispersity index (PDI), describes the 
heterogeneity of a solution:  the greater the number, the greater the differences between 
particles.  For these experiments, a 0.2µm syringe filter was used to reduce the diameters 
of the liposomes.  
To understand the data from some of the samples, more discussion may be 
helpful.  The second 1.0mg/mL sample was sonicated (another method to reduce 





Table 4.1. Raw FOQELS Data on Syringe-extruded Liposomes. 
Concentration 
(mg/mL) 
Dispersity Index Diameter (nm) 
0.5 0.168 846.9 
0.75 0.430 620.2 
1.0 0.105 588.4 
1.0, sonicated 0.335 477.1 
0.0, blank 0.005 17,249 
 
 
liposomes.  The value of the dispersity index of the blank is sensible but the diameter is 
extremely large.  This is most likely due to the size of the water molecule, approximately 
0.2nm, being too small to be accurately measured by the instrument [101].  
Figures 4.1A and 4.1B display a wide range of liposomal diameters, larger than 
the syringe filter pore and desired sizes (0.2µm and 100nm, repsectively, possibly due to 
fusion of formed liposomes.  Use of the Avanti Mini-extruder yielded smaller, more 
consistent liposomes as shown in Table 4.2.  The exact concentrations are not listed due 
to losses in the syringes, filters, and filter supports.  The difference in dispersity index 
between the lower concentration and the higher one is most likely due to the prevalence 
of liposomes.  More liposomes made a higher concentration for more comparisons.  The 
extruder was used to create the liposomes used in the experiments in the earlier chapters. 
 
 
Table 4.2. FOQELS Measurements of Liposomes Formed with the Mini-extruder. 
Concentration 
(mg/mL) 
Dispersity Index Diameter (nm) 
Low 0.104 166.9 









Figure 4.1. Size Ranges of Syringe-extruded Liposomes as Measured by FOQELS. 
 
 
 4.1.2. Diameters of Wet and Dry Liposomes by Particle Research. The 
following graphs, Figures 4.2 and 4.3, demonstrate the improvement achieved by the use 
of the mini-extruder and highlight some other important points.  For example, the polar 
head groups of phospholipids form hydrogen bonds with water molecules in solution 
[102].  This allows the liposomes to appear larger when size is measured by light scatter 
via measurement of the hydrodynamic diameter [100].  When dried (thus the water is 
removed), the diameters of the liposomes are much smaller as shown in Figure 4.2.  The 
liposomes for these tests appeared to have wet diameters around 120nm whereas the dry 








Figure 4.2. Determined Diameters of Humidified (w) and Dried (d) Liposomes with 
(Dye) and without (Clear) the Flurophore 25-NBD-Cholesterol Added.  
  
 
 Figure 4.3 shows the concentration of liposomes, both humidified (wet) and dried, 
at various diameters.  The trends were very similar in the presence or absence of the 
fluorophore (dye).  The majority of dried liposomes were small (about 25nm or less) 
























Determined Diameters of Humidified and Dried Liposomes
















Concentration of Liposomes at Various Diameters
Dry Clear Wet Clear Dry  Dye Wet Dye
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 One may consider that Figure 4.2 and 4.3 do not show liposomes of the same 
diameters.  For example, the humidified liposomes (w) in Figure 4.2 remain relatively 
stable across the graph whereas the dried liposomes (d) increase to the right.  This may be 
due to the infiltration of water molecules into the testing chamber which could bind to the 
DMPC polar head groups, distorting the light scatter and causing increased diameter 
readings.  In Figure 4.3, on the other hand, the diameters all appear much smaller.  In 
fact, the largest concentration of liposomes shows the smallest diameter.  This makes 
sense when considering the fact that dried liposomes are smaller (not hydrated)—the 
same volume of solution would be much more concentrated.  Likewise, the presence of 
water dilutes the number of liposomes in a volume.  Therefore reducing the 
concentration.  Regarding the concentration of dye-loaded liposomes, less of this sample 
of this variety was tested than sample without the flurophore (dye), thus samples with dye 
have lower concentrations due to less sample being available.  These studies were 
conducted by the Center of Excellence for Aerospace Particulate Emission Reduction 
Research.   
 
4.2. CHEMICAL ANALYSIS 
 Numerous chemical analyses have been employed over time to investigate 
different facets of liposomes [76,77,103].  The techniques employed with these 
experiments, beyond those described earlier, for determining the containment of TAD 
within liposomes included UV spectrum analysis, FTIR-ATR, low resolution NMR, and 
flow injection analysis.   
 4.2.1. UV Spectrum Analysis. UV spectrum analysis appeared to be a sensible 
investigation technique due to the wavelength of absorbance for tadalafil being 284nm 
[104,105].  Figure 4.4 displays the data obtained from the spectrophotometer.  
Unfortunately, no peaks are seen at this point.  The first three samples are blank (empty, 
control) liposomes.  The sample contained undiluted liposomes.  The second sample was 
diluted 1:20 with buffer (PSS without glucose and albumin).  The third sample was 
diluted 1:10.  The tadalafil-loaded liposomes were also tested at a 1:10 dilution.  It is 
possible that the tadalafil peak was not seen because the drug was contained within the 
liposomes.   
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 4.2.2. FTIR-ATR and Low Resolution NMR. FTIR-ATR, Fourier transform 
infrared assay-attenuated total reflectance, and low resolution NMR produced no 
distinguishable results between liposomes containing TAD and those not containing 
TAD.  (Data not shown.)  Tadalafil should have been detectable in the absence of 
liposomes [104,106].  However, due to the closure of these facilities for renovation, 
continued testing and retrial were not possible. 
 
 
Figure 4.4. UV Spectrum Analysis of Liposomes with and without TAD. 
 
 
 4.2.3. Flow Injection Analysis. Lastly, flow injection analysis (HPLC without 
the column) was performed using the Hitachi LaChrom Elite with a flow rate of 
0.5mL/min.  This method was used because there was some concern that the liposomes 
could damage or be trapped within the HPLC column. The samples tested and peak 
results obtained are listed in Table 4.3.  As can be seen, some samples produced more 
peaks than others.  The diode array detector (L-2455) provided the results listed in the 
shaded columns.  The data in the last three columns came from the refractive index 
detector (L-2490).  Unfortunately, once again, the data was inconclusive.  It may have 
been beneficial to have tested a variety of columns or to have tried a different HPLC.  Or, 
perhaps a contaminant in the mobile phase (methanol) led to these results.  More testing 





























Table 4.3. Peak Data from HPLC of Samples with and without Liposomes and TAD. 
Sample Diode   Array Detector Refractive Index Data 
TAD in MeOH 0.67   1.15   
Blank liposomes 0.67   1.16   
TAD liposomes 0.62 1.03 1.67 1.54   
Supernatant of blank lip. 0.63 1.04 1.68 1.55   
Supernatant of TAD lip. 0.62 1.05 1.75 1.55   
Buffer 0.63 1.05 1.72 1.57   
Chloroform 0.65 1.07 1.48 1.57   
Chloroform w/blank lip. 0.61 0.7 0.79 0.99 1.46 9.2 
Chloroform w/TAD lip. 0.61 0.7 0.79 0.99 1.46 9.89 
























Although the pulmonary circulation must, at all times, accept the entire cardiac 
output, vascular pressure in the lung is vastly lower than in the systemic circulation.  This 
is accomplished by virtue of the construction of the vascular bed in the lung such that 
increases in blood flow are accommodated by the recruitment of previously non- or 
under-perfused vessels and/or by distension of perfused vessels [107].  However, active 
vasodilation via the local synthesis and release of vasodilators including NO and PGI2 is 
also a critical determinant of PVR [3,108].  In addition, it is now recognized that 
circulating erythrocytes contribute to levels of vascular resistance in the lung.  These cells 
release ATP, a potent stimulus for NO synthesis, in response to increases in mechanical 
deformation as would occur as a result of pulmonary vasoconstriction or increases in 
flow velocity [16,109].   
In humans with PAH, by definition, PVR is greater than normal.  Although the 
underlying mechanisms responsible for the development and progression of PAH are not  
fully understood, it is clear that the ability of PAH erythrocytes fail to release ATP in 
response to mechanical deformation [13].   
Two of the treatments for PAH that have resulted in reductions in PVR as well as  
prolongation of life are the administration of PGI2 analogs and PDE5 inhibitors, alone or 
in combination [27,28].  It has been shown that human erythrocytes possess a PGI2 
receptor [7] as well as PDE5 [20] (Figure 1).  Importantly, both healthy human and PAH 
erythrocytes release ATP in response to PGI2 analogs and the magnitude of that release is 
increased in the presence of PDE5 inhibitors [26,29].  Here we extend that observation 
and report that the synergism between these drugs is potentially clinically important since 
concentrations of UT-15C that alone do not stimulate ATP release do so in the presence 
of PDE5 inhibitors (Figures 3.1 and 3.6). 
Unfortunately, in the treatment of PAH, PGI2 analogs and PDE5 inhibitors in 
combination can have unwanted side effects including headache, flushing and systemic 
hypotension that can limit the amounts of the drugs that can be administered [25,33].  In 
the present study we investigated the overall hypothesis that a PDE5 inhibitor delivered 
selectively to erythrocytes via liposomes would potentiate UT-15C-induced ATP release.  
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Such an approach could result in decreased side effects from both drugs without 
diminishing their effectiveness in the treatment of PAH. 
Liposomes are small lipid vesicles that can target the delivery of drugs to specific 
cell types [37,85].  The feasibility of this approach for the delivery of PDE inhibitors to 
human erythrocytes is demonstrated by the report that a PDE3 inhibitor, CILO, could be 
incorporated into liposomes and effectively delivered to erythrocytes from humans with 
DM2 exposed to low oxygen tension to affect an increase in ATP release [42].   
Here we report that in addition to CILO, liposomes constructed of DMPC are 
capable of delivering PDE5 inhibitors to human erythrocytes (Figures 3.2 and 3.6).  It is 
of interest that, although liposomes containing the PDE3 inhibitor, CILO, restored low 
oxygen-induced ATP release from erythrocytes of humans with DM2 [42], this approach 
was not successful here (Figure 3.2).  There are several possible explanations for this 
result.  First, the signaling pathway stimulated by exposure of erythrocytes to low oxygen 
is not the same as that associated with activation of the IPR (Figures 1.1 and 1.2) 
[9,13,22].  Second, the amount of PDE3 inhibitor required may be greater in the IPR 
pathway.  Finally, the IPR pathway is not defective in PAH erythrocytes while the low 
oxygen pathway is clearly compromised in erythrocytes of humans with DM2 [70].  
Notwithstanding, the finding that in spite of the fact that PDE3 and 5 inhibitors were 
delivered with liposomes of the same composition, only PDE5 inhibitors were effective 
in augmenting  UT-15C-induced ATP release.  Thus, the response to PDE5 inhibitors 
cannot be attributed to non-specific liposome-erythrocyte interactions.  
 The extent of liposome binding to erythrocytes was evaluated using flow 
cytometry.  A fluorophore was incorporated into DMPC liposomes.  Fluorescence was 
detected when liposomes alone or erythrocytes that had been incubated with labeled 
liposomes were passed through the device.  Based on the size of labeled particles 
detected when erythrocytes that had been incubated with labeled liposomes were studied, 
it can be concluded that few liposomes failed to interact with the erythrocyte membranes.  
This is confirmed by the finding that there was no flurophore detected in the supernatant 
of erythrocytes after interaction with labeled liposomes suggesting that the majority of 
the liposomes were bound to the erythrocytes.  It was also important to establish that 
DMPC liposomes of this construction do not alter the rheological properties of human 
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erythrocytes. Here it is reported that there were no detectable rheological differences 
between erythrocytes incubated with or without liposomes. 
 The components that are used to construct liposomes for drug delivery must take 
into account the characteristics of the drug to be delivered and the cell that is the target 
for the liposome.  Consequently, a number of different liposome formulations for 
different purposes have been reported [38,42,74].  It has been suggested that adding 
cholesterol [82,83,110] or a negative surface charge [111,112] may be beneficial in 
targeting liposomes to erythrocytes.  Another potentially important issue in our study is 
that TAD has more aromatic rings than does CILO or ZAP.  For that reason, the initial 
attempts to incorporate TAD into liposomes involved the use of formulations with added 
cholesterol or PS.  Neither of these formulations proved satisfactory (Figure 3.5).  Use of 
cholesterol-containing liposomes stimulated excessively high baseline ATP release 
(Figure 3.5A).  In marked contrast, in the presence of PS-containing liposomes, UT-15C 
did not stimulate ATP release (Figure 3.5B).   However, DMPC liposomes were loaded 
with TAD and, in the presence of these liposomes, UT-15C again stimulated erythrocyte 
ATP release (Figure 3.6).  These studies illustrate the importance of selecting the optimal 
liposomal formulation for drug encapsulation and delivery.   
 In conclusion, these studies demonstrate that liposomal delivery of PDE5 
inhibitors is feasible and that such an approach potentiates UT-15C induced ATP release.  
The findings are consistent with the hypothesis that directed delivery of this class of 
drugs to erythrocytes of humans with PAH could be a new and important method to 
augment PGI2 analog-induced ATP release from these cells.  Such an approach could 
significantly limit side effects of both drugs without compromise of their therapeutic 









6.  FUTURE DIRECTIONS 
 Future experiments that could aid in bringing this potential treatment method 
closer to fruition include the testing of liposome storage, the creation of liposomal 
formulations with erythrocyte-specific antibodies, and testing these liposomes in vivo.  
These efforts could be applied for both PDE3 and PDE5 inhibitors.  Better chemical 
analyses should also be performed.  It is important to determine that the supernatant does 
not contain the drug.  Although some flow cytometry tests were performed, more robust 
investigation into the binding of liposomes to erythrocytes could utilize fluorescing 
antibodies that are quenched when absorbed into the cell.  More in-depth and complete 
chemical analyses could be made.  And, ATP tests attempting to increase ATP release 
from UT-15C-stimulated erythrocytes using the liposomal supernatant would be 
beneficial experiments to conduct.  Successful tests using blood from patients with PAH 
are critical before clinical trials can be made with PAH patients to provide actual 
evidence of increased drug efficacy with reduced side effects.  The use of liposomes is 
increasing growing but slowly.  The potential to improve drug delivery with reduced 
negative consequences is significant.  The variety of drugs that can be encapsulated 
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